CLINICAL_TRIALS
trial_result
· 2022-03-11
Clinical Trial Update: Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers [Phase 1, Phase 2]
Summary
Phase 1/2 trial of IMCnyeso in NY-ESO-1 and/or LAGE-1A positive cancers was terminated; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Immunocore Ltd | Conditions: Select Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-11